Cohance Lifesciences (BOM:543064) Stock Based Compensation: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543064 Cohance Lifesciences Ltd BOM:543064
82 GF Score
Price ₹450.65
GF Value ₹795.29
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Cohance Lifesciences Stock Based Compensation?

Cohance Lifesciences BOM:543064 -0.73% 82 Stock Based Compensation is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:543064 with a GF Score™ of 82/100 and a GF Value™ of ₹795.29 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Cohance Lifesciences's Stock Based Compensation for the three months ended in Jun. 2026 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Cohance Lifesciences Stock Based Compensation Related Terms

Cohance Lifesciences Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Cohance Lifesciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cohance Lifesciences Stock Based Compensation Chart

Cohance Lifesciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 19.70 216.20 -38.10

Cohance Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:543064
82GF Score
Cohance Lifesciences Ltd BOM:543064
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cohance Lifesciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Cohance Lifesciences (BOM:543064) has a Stock Based Compensation of ₹0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cohance Lifesciences and its competitors.
Is Cohance Lifesciences' Stock Based Compensation too high?
Cohance Lifesciences' current Stock Based Compensation is ₹0 Mil. Overall, Cohance Lifesciences has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Stock Based Compensation compare to ZTS?
Cohance Lifesciences' Stock Based Compensation of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cohance Lifesciences and its competitors. Cohance Lifesciences's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹795.29, compared to a current price of ₹450.65 — trading 43.3% below its estimated fair value. The current Stock Based Compensation is ₹0 Mil. Cohance Lifesciences' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Stock Based Compensation is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?

Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued. The current stock price of ₹450.65 is trading 43.3% below its estimated GF Value™ of ₹795.29. GuruFocus considers Cohance Lifesciences to be Significantly Undervalued.

Key valuation signals for BOM:543064:

  • Stock Based Compensation: ₹0 Mil
  • GF Value™: ₹795.29 vs. price of ₹450.65 (43.3% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cohance Lifesciences Business Description

Other Exchanges COHANCE:India
Address Hitech City Road, Panmaktha Plot, 1, 202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad Knowledge City TSIIC Raidurg, Opposite IKEA, Hyderabad, TG, IND, 500081
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
82GF Score

Get the complete analysis for BOM:543064

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹450.65
Price
₹795.29
GF Value